Comparative Pharmacology
Head-to-head clinical analysis: KIMIDESS versus NORCEPT E 1 35 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIMIDESS versus NORCEPT E 1 35 28.
KIMIDESS vs NORCEPT-E 1/35 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
Combination estrogen (ethinyl estradiol) and progestin (norethindrone) contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, and alters endometrial lining.
5 mg orally once daily, with or without food.
1 tablet orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Norethindrone: 5-14 hours; ethinyl estradiol: 13-27 hours. The terminal half-life of norethindrone is about 10 hours, allowing once-daily dosing; ethinyl estradiol's longer half-life contributes to steady-state concentrations within 3-5 days.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Renal (primarily as metabolites) and fecal; approximately 50-60% excreted in urine, 30-40% in feces. Ethinyl estradiol and norethindrone are extensively metabolized via hydroxylation and conjugation; glucuronide and sulfate conjugates are eliminated in urine and bile.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive